Bristol Myers Squibb Company $BMY Shares Acquired by Mirabella Financial Services LLP

Mirabella Financial Services LLP lifted its stake in shares of Bristol Myers Squibb Company (NYSE:BMY) by 158.6% during the third quarter, Holdings Channel reports. The firm owned 40,545 shares of the biopharmaceutical company’s stock after purchasing an additional 24,867 shares during the quarter. Mirabella Financial Services LLP’s holdings in Bristol Myers Squibb were worth $1,825,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Gateway Investment Advisers LLC boosted its holdings in shares of Bristol Myers Squibb by 10.0% in the third quarter. Gateway Investment Advisers LLC now owns 113,457 shares of the biopharmaceutical company’s stock worth $5,117,000 after buying an additional 10,284 shares during the period. CWA Asset Management Group LLC increased its position in shares of Bristol Myers Squibb by 25.9% in the third quarter. CWA Asset Management Group LLC now owns 150,359 shares of the biopharmaceutical company’s stock worth $6,781,000 after acquiring an additional 30,909 shares in the last quarter. Stephens Inc. AR raised its holdings in shares of Bristol Myers Squibb by 13.5% during the third quarter. Stephens Inc. AR now owns 273,343 shares of the biopharmaceutical company’s stock valued at $12,328,000 after acquiring an additional 32,476 shares during the period. Railway Pension Investments Ltd lifted its position in shares of Bristol Myers Squibb by 3.7% in the 3rd quarter. Railway Pension Investments Ltd now owns 1,139,600 shares of the biopharmaceutical company’s stock valued at $51,396,000 after acquiring an additional 40,300 shares in the last quarter. Finally, Norges Bank acquired a new position in Bristol Myers Squibb in the 2nd quarter worth approximately $1,554,154,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on BMY. Truist Financial set a $65.00 target price on shares of Bristol Myers Squibb in a research note on Wednesday, December 3rd. UBS Group reaffirmed a “buy” rating and issued a $70.00 target price on shares of Bristol Myers Squibb in a research report on Friday, March 6th. Piper Sandler reiterated an “overweight” rating and set a $75.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Cantor Fitzgerald reissued a “neutral” rating on shares of Bristol Myers Squibb in a research note on Monday, November 24th. Finally, Royal Bank Of Canada initiated coverage on Bristol Myers Squibb in a research report on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 price objective for the company. Nine analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $61.41.

Bristol Myers Squibb Trading Down 2.0%

Shares of NYSE:BMY opened at $58.17 on Friday. The firm has a fifty day moving average of $58.57 and a two-hundred day moving average of $51.74. The firm has a market capitalization of $118.46 billion, a P/E ratio of 16.86, a price-to-earnings-growth ratio of 0.17 and a beta of 0.26. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $62.89. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The company had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. During the same period last year, the company posted $1.67 earnings per share. The company’s revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be given a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 4.3%. The ex-dividend date of this dividend is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio is presently 73.04%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.